Amgen Ranked Top Pharma Company by Patient Organizations in U.S.

Amgen has been ranked number one among pharma peer companies and number three overall by patient organizations in the PatientView Corporate Reputation Survey for 2024. The survey reflects the perspectives of hundreds of patient advocacy organizations and measures how pharmaceutical companies are perceived by the communities they serve. Amgen has maintained these rankings from the previous year and was praised for its integrity, patient centricity, access to medicines, transparency in pricing and funding, products of benefit, and long-term relationships with patient groups.

Amgen Inc. has once again been recognized as the top pharma company among its peers and ranked third overall in the U.S. by patient organizations in the 2024 PatientView Corporate Reputation Survey [2]. The annual survey, which gathers perspectives from hundreds of patient advocacy organizations, reflects how pharmaceutical companies are perceived by the communities they serve. Amgen has maintained these rankings from the previous year, demonstrating consistent high regard from patient groups.

The survey praises Amgen for its integrity, patient centricity, access to medicines, transparency in pricing and funding, products of benefit, and long-term relationships with patient groups. These accolades highlight Amgen's commitment to improving patient outcomes and maintaining a strong reputation within the pharmaceutical industry.

Amgen's performance in the survey is particularly notable given the intense competition in the pharmaceutical sector. The company's ability to maintain these rankings year after year indicates a robust and well-regarded corporate reputation, which can be a significant advantage in the market.

For investors and financial professionals, Amgen's high ranking in the PatientView survey underscores the company's strong commitment to its stakeholders, including patients and patient advocacy organizations. This commitment can translate into long-term growth and stability, making Amgen a solid choice for investment consideration.

References:
[1] https://www.marketbeat.com/instant-alerts/filing-banque-transatlantique-sa-grows-holdings-in-amgen-inc-amgn-2025-09-03/
[2] https://www.marketscreener.com/news/amgen-once-again-recognized-as-top-pharma-company-by-u-s-patients-ce7d59d9dd8cfe22